Valuation: Shivalik Rasayan Limited

Market Cap 3.49B 36.49M 32.01M 29.64M 27.28M 51.59M 52.59M 353M 139M 1.72B 137M 134M 5.92B P/E 2024
69.1x
P/E 2025 59.1x
Enterprise Value 4.26B 44.51M 39.04M 36.16M 33.27M 62.93M 64.15M 431M 169M 2.09B 167M 163M 7.23B EV / Sales 2024
3.49x
EV / Sales 2025 3.4x
Free-Float
40.79%
Yield 2024
0.09%
Yield 2025 0.08%
May. 27 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
May. 27 Shivalik Rasayan Limited Announces Resignation of Sanjay Bansal as Non-Executive Director, Effective May 27, 2026 CI
May. 27 Shivalik Rasayan Limited Recommends Final Dividend for the Financial Year 2025-26 CI
May. 27 Shivalik Rasayan Ltd March-quarter consol net profit 45.3 million rupees RE
Feb. 13 Shivalik Rasayan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
Nov. 14 Shivalik Rasayan Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-09-29 Shivalik Rasayan Limited Approves the Re-Designation of Mr. Ashwani Kumar Sharma as a Non-Executive, Non-Independent Director CI
25-08-12 Shivalik Rasayan Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-30 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
25-05-29 Shivalik Rasayan Limited announces Annual dividend, payable on October 27, 2025 CI
25-04-23 Medicamen Biotech Limited announced that it has received INR 535.6816 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD and other investors CI
25-02-25 Medicamen Biotech Limited announced that it expects to receive INR 775.7875 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD CI
24-10-04 Shivalik Rasayan Gets US FDA Nod for Pharmaceutical Ingredient Facility in Gujarat; Shares Rise 3% MT
1 day-3.18%
1 week-6.36%
Current month-9.27%
1 month-4.57%
3 months-19.07%
6 months-36.09%
Current year-39.61%
1 week 213.55
Extreme 213.55
229
1 month 206
Extreme 206
245
Current year 206
Extreme 206
371.3
1 year 206
Extreme 206
652.75
3 years 206
Extreme 206
890.05
5 years 206
Extreme 206
1,196.8
10 years 36.16
Extreme 36.16
1,196.8
Manager TitleAgeSince
Chief Executive Officer 64 2018-11-16
Director of Finance/CFO - 2001-10-31
Chief Tech/Sci/R&D Officer - 2024-01-10
Director TitleAgeSince
Chairman 61 2002-02-22
Director/Board Member 67 2003-07-17
Director/Board Member - 2018-11-12
Date Insider Type Main position Quantity % Market Cap.
24-06-30Don 21,500 0.1382%
24-06-25Sell 108,500 0.6973%
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%-6.36%-59.15%-72.53% 36.65M
+0.13%-0.65%+17.40%+57.17% 57.3B
+0.11%-.--%-.--%-.--% 12.96B
-3.93%-1.94%+42.59%+184.84% 11.12B
-2.97%-13.53%+17.03%+51.55% 7.33B
+1.55%-2.48%-28.73%-16.38% 6.26B
+0.04%-3.11%-6.54%+82.00% 5.8B
-0.47%-2.41%-9.30%-8.08% 5.26B
-0.25%-0.88%+19.05%+32.11% 4.65B
-1.40%-2.90%-36.44%-29.76% 4.15B
Average -1.04%-2.59%-4.41%+28.09% 11.49B
Weighted average by Cap. -0.48%-1.37%+11.00%+52.78%

Financials

2024 2025
Net sales 2.72B 28.37M 24.88M 23.05M 21.21M 40.11M 40.89M 275M 108M 1.33B 107M 104M 4.61B 3.1B 32.34M 28.37M 26.27M 24.17M 45.72M 46.61M 313M 123M 1.52B 121M 119M 5.25B
Net income 127M 1.33M 1.17M 1.08M 993K 1.88M 1.92M 12.86M 5.05M 62.45M 4.99M 4.88M 216M 167M 1.74M 1.53M 1.42M 1.3M 2.47M 2.51M 16.89M 6.62M 81.99M 6.55M 6.41M 283M
Net Debt 482M 5.04M 4.42M 4.09M 3.77M 7.12M 7.26M 48.79M 19.14M 237M 18.92M 18.51M 818M 768M 8.02M 7.03M 6.51M 5.99M 11.34M 11.56M 77.65M 30.45M 377M 30.11M 29.46M 1.3B
Logo Shivalik Rasayan Limited
Shivalik Rasayan Limited is an India-based company. The Company’s segments are engaged in agrochemicals, active pharma ingredients (API), and pharma formulation. It is the producer of Malathion Technical and Dimethoate Technical. Malathion Technical is a non-systemic, wide spectrum organophosphorus (OP) based contact insecticide. Dimethoate Technical is used in preparation of formulations used in the control of a range of insects and mites. It also manufactures organophosphorus-based insecticides and chemicals. It has a diverse product range and product mix in order to serve consumer requirements. The APIs are being developed and manufactured in the niche area of oncology, ARVs, cardiovascular, metabolic disorders and immunology. It offers solutions from product selection to development to commercialization for a range of oncology and non-oncology products. The Company’s oncology products include Azacitidine, Busulfan, Bortezomib, and various others.
Employees
275
Date Price Change Volume
26-07-13 214.90 -3.18% 4,087
26-07-10 ₹221.95 -2.18% 2,161
26-07-09 ₹226.90 +3.63% 922
26-07-08 ₹218.95 -1.51% 2,231
26-07-07 ₹222.30 -5.00% 1,533
  1. Stock Market
  2. Stocks
  3. SHIVALIK Stock